Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMY, BDSX, ACAD, ELUT, UTHR, and represent 52.19% of Birchview Capital's stock portfolio.
- Added to shares of these 10 stocks: ACAD, EQT, CSTL, ATEC, KALV, TMCI, TVTX, INBX, BPMC, DCGO.
- Started 5 new stock positions in TMCI, BPMC, ALMS, QURE, EQT.
- Reduced shares in these 10 stocks: Silk Road Medical Inc Common, HROW, ETRN, NBIX, ELUT, OVV, , G1 Therapeutics, BMY, BLUE.
- Sold out of its positions in ETRN, XOM, G1 Therapeutics, Silk Road Medical Inc Common.
- Birchview Capital was a net seller of stock by $-6.4M.
- Birchview Capital has $115M in assets under management (AUM), dropping by 6.72%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Birchview Capital
Birchview Capital holds 61 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 30.8 | $36M | 686k | 51.74 |
|
|
| Biodesix (BDSX) | 8.6 | $9.9M | 5.5M | 1.78 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 5.3 | $6.2M | +59% | 400k | 15.38 |
|
| Aziyo Biologics (ELUT) | 4.4 | $5.0M | -14% | 1.3M | 3.81 |
|
| United Therapeutics Corporation (UTHR) | 3.1 | $3.6M | 10k | 358.35 |
|
|
| Prothena Corp SHS (PRTA) | 3.0 | $3.5M | +2% | 210k | 16.73 |
|
| Neurocrine Biosciences (NBIX) | 3.0 | $3.5M | -28% | 30k | 115.22 |
|
| Corcept Therapeutics Incorporated (CORT) | 3.0 | $3.4M | 74k | 46.28 |
|
|
| Harrow Health (HROW) | 2.8 | $3.3M | -51% | 73k | 44.96 |
|
| Quidel Corporation | 2.7 | $3.1M | 68k | 45.60 |
|
|
| Foghorn Therapeutics (FHTX) | 2.6 | $3.0M | 321k | 9.31 |
|
|
| Axogen (AXGN) | 2.4 | $2.8M | 197k | 14.02 |
|
|
| Phreesia (PHR) | 2.3 | $2.6M | 115k | 22.79 |
|
|
| Stoke Therapeutics (STOK) | 2.2 | $2.6M | 210k | 12.29 |
|
|
| Protagonist Therapeutics (PTGX) | 1.9 | $2.2M | 48k | 45.00 |
|
|
| Travere Therapeutics (TVTX) | 1.8 | $2.1M | +21% | 148k | 13.99 |
|
| Masimo Corporation (MASI) | 1.8 | $2.0M | 15k | 133.33 |
|
|
| Encana Corporation (OVV) | 1.7 | $2.0M | -29% | 52k | 38.31 |
|
| Docgo (DCGO) | 1.5 | $1.7M | +11% | 515k | 3.32 |
|
| Castle Biosciences (CSTL) | 1.4 | $1.7M | +70% | 58k | 28.52 |
|
| Alkermes SHS (ALKS) | 1.2 | $1.4M | 50k | 27.99 |
|
|
| EQT Corporation (EQT) | 1.1 | $1.3M | NEW | 35k | 36.64 |
|
| Alphatec Holdings (ATEC) | 1.0 | $1.1M | +125% | 198k | 5.56 |
|
| Kalvista Pharmaceuticals (KALV) | 0.8 | $950k | +78% | 82k | 11.58 |
|
| Kiniksa Pharmaceuticals | 0.7 | $750k | 30k | 24.99 |
|
|
| 10x Genomics Cl A Com (TXG) | 0.6 | $677k | 30k | 22.58 |
|
|
| Halozyme Therapeutics (HALO) | 0.5 | $572k | 10k | 57.24 |
|
|
| Accelr8 Technology | 0.5 | $556k | 325k | 1.71 |
|
|
| Cytokinetics (CYTK) | 0.5 | $528k | 10k | 52.80 |
|
|
| Inhibrx Biosciences (INBX) | 0.4 | $503k | +165% | 32k | 15.66 |
|
| Keros Therapeutics (KROS) | 0.4 | $407k | 7.0k | 58.07 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.4 | $404k | 14k | 28.84 |
|
|
| Treace Med Concepts (TMCI) | 0.3 | $396k | NEW | 68k | 5.80 |
|
| Xenon Pharmaceuticals (XENE) | 0.3 | $394k | 10k | 39.37 |
|
|
| Karyopharm Therapeutics (KPTI) | 0.3 | $390k | 470k | 0.83 |
|
|
| Coherus Biosciences (CHRS) | 0.3 | $387k | +37% | 372k | 1.04 |
|
| Arvinas Ord (ARVN) | 0.3 | $370k | 15k | 24.63 |
|
|
| Progyny (PGNY) | 0.3 | $369k | 22k | 16.76 |
|
|
| Biohaven Pharmaceutical Holding | 0.3 | $368k | 7.4k | 49.97 |
|
|
| Axsome Therapeutics (AXSM) | 0.3 | $360k | 4.0k | 89.87 |
|
|
| Cullinan Oncology (CGEM) | 0.3 | $335k | 20k | 16.74 |
|
|
| Wave Life Sciences SHS (WVE) | 0.3 | $328k | 40k | 8.20 |
|
|
| Springworks Therapeutics (SWTX) | 0.3 | $320k | 10k | 32.04 |
|
|
| Novocure Ord Shs (NVCR) | 0.3 | $313k | 20k | 15.63 |
|
|
| Sarepta Therapeutics (SRPT) | 0.3 | $312k | 2.5k | 124.89 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.3 | $304k | 40k | 7.60 |
|
|
| Amicus Therapeutics (FOLD) | 0.3 | $299k | 28k | 10.68 |
|
|
| Blueprint Medicines (BPMC) | 0.2 | $250k | NEW | 2.7k | 92.50 |
|
| Xencor (XNCR) | 0.2 | $247k | 12k | 20.11 |
|
|
| Gossamer Bio (GOSS) | 0.1 | $136k | 138k | 0.99 |
|
|
| Bluebird Bio (BLUE) | 0.1 | $110k | -32% | 211k | 0.52 |
|
| Alumis (ALMS) | 0.1 | $107k | NEW | 10k | 10.68 |
|
| Liquidia Technologies (LQDA) | 0.1 | $100k | 10k | 10.00 |
|
|
| Uniqure Nv SHS (QURE) | 0.1 | $99k | NEW | 20k | 4.93 |
|
| Inflarx Nv (IFRX) | 0.1 | $77k | 50k | 1.53 |
|
|
| 2seventy Bio (TSVT) | 0.1 | $75k | -11% | 16k | 4.72 |
|
| Ventyx Biosciences (VTYX) | 0.1 | $63k | 29k | 2.18 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $59k | 16k | 3.68 |
|
|
| Cabaletta Bio (CABA) | 0.0 | $47k | 10k | 4.72 |
|
|
| Outset Med (OM) | 0.0 | $6.8k | 10k | 0.68 |
|
|
| Cero Therapeutics Holdings Class A Com (CERO) | 0.0 | $1.2k | 13k | 0.09 |
|
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2024 Q3 filed Nov. 14, 2024
- Birchview Capital 2024 Q2 filed Aug. 13, 2024
- Birchview Capital 2024 Q1 filed May 14, 2024
- Birchview Capital 2023 Q4 filed Feb. 14, 2024
- Birchview Capital 2023 Q3 filed Nov. 14, 2023
- Birchview Capital 2023 Q2 filed Aug. 8, 2023
- Birchview Capital 2023 Q1 filed May 12, 2023
- Birchview Capital 2022 Q4 filed Feb. 3, 2023
- Birchview Capital 2022 Q3 restated filed Nov. 28, 2022
- Birchview Capital 2022 Q3 filed Nov. 7, 2022
- Birchview Capital 2022 Q2 filed Aug. 12, 2022
- Birchview Capital 2022 Q1 filed May 13, 2022
- Birchview Capital 2021 Q4 filed Feb. 14, 2022
- Birchview Capital 2021 Q3 filed Nov. 12, 2021
- Birchview Capital 2021 Q2 filed Aug. 10, 2021
- Birchview Capital 2021 Q1 filed May 14, 2021